Focused On-demand Library for Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99640

UPID:

PMYT1_HUMAN

Alternative names:

Myt1 kinase

Alternative UPACC:

Q99640; B3KUN8; B4DXD4; D3DUA4; F8W164; I3L1V2; O14731; Q7LE24; Q8TCM9

Background:

Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase, also known as Myt1 kinase, plays a pivotal role in cell cycle regulation. It acts as a negative regulator of the G2 to M transition by phosphorylating CDK1 kinase, especially when CDK1 is complexed with cyclins, primarily on 'Thr-14'. Myt1 kinase is also implicated in Golgi fragmentation and may have a role in phosphorylating CDK1 on 'Tyr-15', though its tyrosine kinase activity may be indirect. It is considered a potential downstream target of the Notch signaling pathway during eye development.

Therapeutic significance:

Understanding the role of Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase could open doors to potential therapeutic strategies.